Nominations for the 2019 eyeforpharma awards are currently open.
In a world where true value matters and trust is critical; what are we rewarding?
It’s time for pharma to show its true colors and provide the maximum value to the greatest number of patients.
As we transform our industry, it’s vital to support the best work - and support it today, in 2019.
Nominations are now open for the eyeforpharma Awards 2019 - Click HERE to find out more.
We have 13 categories including new awards that celebrate innovation, disruption, entrepreneurs and pioneers.
How are you adding value? Find out how you can reward and be rewarded - Click HERE to find out more.
Categories include:
• New: Most Promising Pilot
This award is for an experimental initiative which has the potential to disrupt the status quo.
• New: Most Valuable Education/Awareness Initiative
This award is for an initiative that has raised the profile and visibility of a disease, cause, health concern, population or treatment.
• New: Most Valuable Data & Insights Initiative
This award is for an initiative that harnesses data (internal or RWD), AI, ML or analytics to reveal valuable insights, ultimately resulting in new opportunities for better patient care.
• Most Valuable Healthcare/HCP Initiative
The winner of this award will be an innovative project which has delivered tangible working and healthcare improvements, both in the long and short term, to healthcare professionals.
• Most Valuable Collaboration
The winner of this award will be the creator of a pharma-pharma or pharma-non pharma initiative which clearly brings a new proposition to either HCPs, payers and/or healthcare systems.
Download your Entry Pack here to find out more.
If you have any questions about the eyeforpharma Awards 2019, email Liz Swift at eswift@eyeforpharma.com
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.